ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0939

Maintenance of Remission After Withdrawal of Etanercept or Methotrexate in Patients with Rheumatoid Arthritis in Sustained Remission on Combination Therapy: Results from a Randomized, Double-blind, Controlled Trial
Abstract Number: 0940

In Patients with Inflammatory Arthritides Central Pain Sensitization Is Strictly Associated with Functional Disability
Abstract Number: 0941

MDHAQ/RAPID3 (multidimensional Health Assessment Questionnaire/routine Assessment of Patient Index Data) Levels Are Elevated in Rheumatology Patients Who Meet 2011 Fibromyalgia (FM) or MDHAQ/FAST3 (fibromyalgia Assessment Screening Tool) Criteria
Abstract Number: 0942

Use of Medical Cannabis by Patients with Fibromyalgia: A Prospective Cross-sectional Study
Abstract Number: 0943

Reliability and Validity Issues in Fibromyalgia Diagnosis
Abstract Number: 0944

Obstructive Sleep Apnea in Fibromyalgia Patients: A Meta-analysis
Abstract Number: 0945

Neutrophils Mediate Kidney Inflammation Following Acute Skin Exposure to UV Light
Abstract Number: 0946

ENPP1 Regulates UV Light Triggered Type I Interferon Response in the Skin
Abstract Number: 0947

STING Gain-of-Function in Radio-resistant Cells Supports a Lymphocyte Dependent Auto-inflammatory Lung Disease
Abstract Number: 0948

Mass Cytometry Reveals Activation Heterogeneity of Circulating Neutrophils in Systemic Lupus Erythematosus
Abstract Number: 0949

SLAMF7 Engagement Drives Monocyte Super-Activation in Acute and Chronic Inflammation
Abstract Number: 0950

The Association Between Gout and Cardiovascular Disease Outcomes: Assessment and Recalibration of Individual-level Primary Prevention Risk Prediction Equations in Approximately 450,000 New Zealanders
Abstract Number: 0951

The Comparative Effect of Exposure to Various Risk Factors on the Risk of Hyperuricaemia: Diet Has a Weak Causal Effect
Abstract Number: 0952

Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial
Abstract Number: 0953

Long-term Xanthine Oxidase Inhibitor Treat to Target Urate Lowering Therapy Coordinately Re-wires the Mononuclear Leukocyte Mitochondrial and Inflammatory Proteome in Gout

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].